A Follow-up Study to Assess the Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 01 Feb 2018 Planned End Date changed from 30 Jun 2020 to 31 Dec 2020.
- 01 Feb 2018 Planned primary completion date changed from 30 Jun 2020 to 31 Dec 2020.
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.